These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: a pathologic and molecular study of 18 cases. Prieto-Granada C; Zhang L; Chen HW; Sung YS; Agaram NP; Jungbluth AA; Antonescu CR Genes Chromosomes Cancer; 2015 Jan; 54(1):28-38. PubMed ID: 25231134 [TBL] [Abstract][Full Text] [Related]
9. Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. Puls F; Agaimy A; Flucke U; Mentzel T; Sumathi VP; Ploegmakers M; Stoehr R; Kindblom LG; Hansson M; Sydow S; Arbajian E; Mertens F Am J Surg Pathol; 2020 May; 44(5):594-606. PubMed ID: 31913156 [TBL] [Abstract][Full Text] [Related]
10. Primary Renal Hybrid Low-grade Fibromyxoid Sarcoma-Sclerosing Epithelioid Fibrosarcoma: An Unusual Pediatric Case With EWSR1-CREB3L1 Fusion. Mok Y; Pang YH; Sanjeev JS; Kuick CH; Chang KT Pediatr Dev Pathol; 2018; 21(6):574-579. PubMed ID: 29426275 [TBL] [Abstract][Full Text] [Related]
11. In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets. Arbajian E; Puls F; Antonescu CR; Amary F; Sciot R; Debiec-Rychter M; Sumathi VP; Järås M; Magnusson L; Nilsson J; Hofvander J; Mertens F Clin Cancer Res; 2017 Dec; 23(23):7426-7434. PubMed ID: 28939748 [No Abstract] [Full Text] [Related]
12. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Doyle LA; Möller E; Dal Cin P; Fletcher CD; Mertens F; Hornick JL Am J Surg Pathol; 2011 May; 35(5):733-41. PubMed ID: 21415703 [TBL] [Abstract][Full Text] [Related]
13. Sclerosing epithelioid fibrosarcoma - a report of two cases with cytogenetic analysis of FUS gene rearrangement by FISH technique. Rekhi B; Folpe AL; Deshmukh M; Jambhekar NA Pathol Oncol Res; 2011 Mar; 17(1):145-8. PubMed ID: 20499220 [TBL] [Abstract][Full Text] [Related]
14. Sclerosing Epithelioid Fibrosarcoma: A Distinct Sarcoma With Aggressive Features. Warmke LM; Meis JM Am J Surg Pathol; 2021 Mar; 45(3):317-328. PubMed ID: 32769431 [TBL] [Abstract][Full Text] [Related]
15. [A hybrid lesion: Low-grade fibromyxoid sarcoma (LGFMS) and sclerosing epithelioid fibrosarcoma (SEF)]. Kesrouani C; Zemoura L; Trassard M; Laé M Ann Pathol; 2016 Oct; 36(5):351-354. PubMed ID: 27641819 [TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing epithelioid fibrosarcoma of the spine: a single-institution experience. Righi A; Pacheco M; Pipola V; Gambarotti M; Benini S; Sbaraglia M; Frisoni T; Boriani S; Dei Tos AP; Gasbarrini A Histopathology; 2021 Jun; 78(7):976-986. PubMed ID: 33428796 [TBL] [Abstract][Full Text] [Related]
17. Sclerosing epithelioid fibrosarcoma of bone with hybrid features: clinicopathologic, radiologic, and molecular analysis of three cases. Suster DI; Gross JM; Fayad L; Wenokor C; Goldsmith JD; Ward A; Early C; Lazano-Calderon S; Klein MJ Skeletal Radiol; 2024 Feb; 53(2):387-393. PubMed ID: 37524934 [TBL] [Abstract][Full Text] [Related]
18. Sclerosing epithelioid fibrosarcoma: cytologic characterization with histologic, immunohistologic, molecular, and clinical correlation of 8 cases. Porteus C; Gan Q; Gong Y; Pantanowitz L; Henderson-Jackson E; Saeed-Vafa D; Mela N; Peterson D; Ahmad N; Ahmed A; Bui M J Am Soc Cytopathol; 2020; 9(6):513-519. PubMed ID: 32624384 [TBL] [Abstract][Full Text] [Related]
19. A group of sclerosing epithelioid fibrosarcomas with low-level amplified EWSR1-CREB3L1 fusion gene in children. Zhang M; Yu Y; Guan X; Yao X; Jia C; Hong E; Guo Y; He L Pathol Res Pract; 2022 Feb; 230():153754. PubMed ID: 34990868 [TBL] [Abstract][Full Text] [Related]
20. Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years. Blay JY; Tlemsani C; Toulmonde M; Italiano A; Rios M; Bompas E; Valentin T; Duffaud F; Le Nail LR; Watson S; Firmin N; Dubray-Longeras P; Ropars M; Perrin C; Hervieu A; Lebbe C; Saada-Bouzid E; Soibinet P; Fiorenza F; Bertucci F; Boudou P; Vaz G; Bonvalot S; Honoré C; Marec-Berard P; Minard V; Cleirec M; Biau D; Meeus P; Babinet A; Dumaine V; Carriere S; Fau M; Decanter G; Gouin F; Ngo C; Le Loarer F; Karanian M; Meurgey A; Dufresne A; Brahmi M; Chemin-Airiau C; Ducimetiere F; Penel N; Le Cesne A; Eur J Cancer; 2024 Jan; 196():113454. PubMed ID: 38008029 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]